Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LTX-109 for COVID-19
NCT04854928Phase 2Unknown
- Sponsor
- Pharma
- Start
- May 2021
- Primary completion
- Feb 2022
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of voxvoganan in coronavirus disease 2019 (COVID-19), sponsored by Pharma. Status: unknown.
02
Drugs
voxvoganan
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04854928.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04854928.